Kate Surdez
Human Resources Officer presso MIMEDX GROUP, INC.
Profilo
Kate Surdez is currently the Chief Human Resources Officer at MiMedx Group, Inc. She previously worked as a Global Director at AstraZeneca PLC, Director-Human Resources at Frederick Manufacturing Corp., Senior Vice President & Head-Human Resources at Viela Bio, Inc., and Vice President-People at Vaxxinity, Inc. She obtained an undergraduate degree from The University of North Carolina at Wilmington.
Posizioni attive di Kate Surdez
Società | Posizione | Inizio |
---|---|---|
MIMEDX GROUP, INC. | Human Resources Officer | 18/07/2022 |
Precedenti posizioni note di Kate Surdez
Società | Posizione | Fine |
---|---|---|
VAXXINITY, INC. | Human Resources Officer | - |
ASTRAZENECA PLC | Corporate Officer/Principal | - |
Frederick Manufacturing Corp. | Human Resources Officer | - |
VIELA BIO, INC. | Human Resources Officer | - |
Formazione di Kate Surdez
The University of North Carolina at Wilmington | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
ASTRAZENECA PLC | Health Technology |
VAXXINITY, INC. | Health Technology |
MIMEDX GROUP, INC. | Health Technology |
Aziende private | 2 |
---|---|
Frederick Manufacturing Corp. | Producer Manufacturing |
Viela Bio, Inc.
Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
- Borsa valori
- Insiders
- Kate Surdez